10-Q: Brainstorm Cell Therapeutics Reports Second Quarter 2024 Results, Secures SPA Agreement for NurOwn Phase 3b Trial

Brainstorm Cell Therapeutics reported its financial results for the second quarter of 2024, highlighting a decrease in operating expenses and progress in its NurOwn clinical program, including a Special Protocol Assessment (SPA) agreement with the FDA.

Summary

• Brainstorm Cell Therapeutics reported a net loss of $5.942 million for the six months ended June 30, 2024, compared to a net loss of $10.388 million for the same period in 2023.
• The company's operating expenses decreased to $5.456 million for the six months ended June 30, 2024, from $10.6 million in the same period of 2023.
• Research and development expenses decreased to $1.883 million for the six months ended June 30, 2024, compared to $5.718 million for the same period in 2023.
• General and administrative expenses also decreased to $3.573 million for the six months ended June 30, 2024, from $4.882 million in the same period of 2023.
• The company had cash, cash equivalents, and restricted cash of $3.648 million as of June 30, 2024.
• Brainstorm raised $6.909 million through financing activities in the first six months of 2024, primarily through at-the-market offerings and a private placement.
• The company received a Special Protocol Assessment (SPA) agreement from the FDA for its planned Phase 3b trial of NurOwn in ALS.
• Brainstorm also reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of the Phase 3b clinical trial for NurOwn.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the SPA agreement and reduced operating expenses, the company's financial situation remains precarious, with ongoing losses, low cash reserves, and the risk of delisting. The legal challenges also add to the negative sentiment.

Positives

• The company successfully obtained an SPA agreement with the FDA for its Phase 3b trial of NurOwn in ALS, validating the clinical trial protocol and statistical analysis.
• Brainstorm achieved alignment with the FDA on the CMC aspects of the NurOwn Phase 3b clinical trial, which is a critical step for regulatory approval.
• The company significantly reduced its operating expenses and net loss compared to the same period last year.
• Brainstorm successfully raised additional capital through at-the-market offerings and a private placement.
• The company has a strong intellectual property portfolio with 27 granted patents and 23 patent applications.

Negatives

• The company continues to incur operating losses and has an accumulated deficit of approximately $221 million.
• Brainstorm is facing potential delisting from the Nasdaq due to non-compliance with minimum bid price and market value requirements.
• The company is involved in ongoing securities class action and derivative lawsuits.
• The company has not yet generated any revenue from operations.
• The company's ability to continue as a going concern is dependent on raising additional capital.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Brainstorm is at risk of being delisted from the Nasdaq if it fails to regain compliance with minimum bid price and market value requirements.
• The company is facing ongoing securities class action and derivative lawsuits, which could result in substantial costs and a diversion of management's attention.
• The company's ability to obtain regulatory approval for NurOwn is uncertain.
• The company's ability to successfully commercialize NurOwn is subject to various risks, including manufacturing, marketing, and competition.

Future Outlook

The company is focused on advancing its NurOwn program, particularly the Phase 3b trial in ALS, and is exploring options for other indications. The company anticipates needing to raise substantial additional financing in the future to fund its operations.

Management Comments

• The company is actively exploring the next steps in support of NurOwn, including publication of emerging clinical data and development of a protocol for an additional clinical study.
• The company is committed to the ALS Community.
• The company is strategically focused on fully executing the clinical development of NurOwn in PMS, reviewing the optimal approach in AD and will consider the best course of action based on recent scientific and regulatory insights.

Industry Context

The company is operating in the competitive biotechnology sector, focusing on cell therapies for neurodegenerative diseases. The company's progress with NurOwn, particularly the SPA agreement with the FDA, is a positive development in the context of the broader industry trend towards innovative treatments for neurological disorders. The company's focus on autologous cell therapies aligns with the growing interest in personalized medicine.

Comparison to Industry Standards

• The company's cash burn rate is high, which is typical for clinical-stage biotech companies. However, the company's cash reserves are relatively low compared to other companies in the sector.
• The company's R&D spending is lower than some of its peers, which may reflect its focus on late-stage clinical development.
• The company's success in obtaining an SPA agreement with the FDA is a positive sign, as it indicates a clear regulatory pathway for its Phase 3b trial. This is a significant milestone compared to other companies that are still in the early stages of clinical development.
• The company's intellectual property portfolio is strong, with 27 granted patents and 23 patent applications, which is comparable to other companies in the cell therapy space.
• The company's ongoing legal challenges are a concern, as they could divert resources and attention from its core business activities. This is a risk that is common among companies in the biotech sector, particularly those that are developing novel therapies.

Management Changes

Legal Proceedings

• The company is involved in a securities class action lawsuit filed by a purported shareholder.
• The company is also involved in four derivative action complaints filed by purported shareholders, which have been consolidated into a single action.

Stakeholder Impact

• Shareholders face the risk of further stock dilution and potential delisting from Nasdaq.
• Employees may be concerned about the company's financial stability and potential job security.
• Patients with ALS and other neurodegenerative diseases may be impacted by the company's ability to continue developing NurOwn.
• The company's ability to secure and maintain research institutions to conduct clinical trials may be affected by its financial situation.

Next Steps

• The company will proceed with its planned Phase 3b clinical trial of NurOwn for the treatment of ALS.
• The company will continue to explore options for other indications for NurOwn.
• The company will actively monitor its market value and bid price to regain compliance with Nasdaq listing requirements.
• The company will continue to seek additional funding to support its operations.

Key Dates

Keywords

NurOwn, ALS, amyotrophic lateral sclerosis, cell therapy, clinical trial, FDA, SPA, biotechnology, neurodegenerative diseases, Mesenchymal Stem Cells, MSC-NTF cells, regulatory approval, Phase 3b trial, CMC, market value, delisting